VEGFA and glioblastoma: Bevacizumab, a humanized monoclonal antibody and inhibitor of VEGFA, is thus a promising anti-VEGF agent to create persistent normalization through pruning vessels and overcoming the recurrence of hypoxia and the emergence of resistance in GBM (192).